Product Images Rivastigmine Tartrate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Rivastigmine Tartrate NDC 54868-6145 by Physicians Total Care, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label-6 mg - 6mg package label

Label-6 mg - 6mg package label

This is a medication package of Rivastigmine, distributed by Physicians Total Care and labeled with an NDC code of 54868-6145-0. There is a lot number, expiration date, and weight information provided.*

rivastigmine-figure01 - rivastigmine fig1

rivastigmine-figure01 - rivastigmine fig1

This appears to be a graph displaying the time course of clinical improvement and decline in ADAS-cog scores for patients completing a 26-week treatment called "Changa rom Baseio". The x-axis is labeled "Weeks During Treatment" and the y-axis is labeled with "ADAS-cog Scores." There are two lines on the graph representing clinical improvement and clinical decline respectively. There is also a legend indicating the meaning of different symbols or colors used in the graph, such as "+" and "M."*

rivastigmine-figure02 - rivastigmine fig2

rivastigmine-figure02 - rivastigmine fig2

rivastigmine-figure03 - rivastigmine fig3

rivastigmine-figure03 - rivastigmine fig3

rivastigmine-figure04 - rivastigmine fig4

rivastigmine-figure04 - rivastigmine fig4

Figure 4 shows the time-course of change on the baseline in ADAS-cog score of a patient completing 26 weeks of treatment. There is also information on clinical improvement and clinical data during treatment.*

rivastigmine-figure05 - rivastigmine fig5

rivastigmine-figure05 - rivastigmine fig5

This is a chart showing the percentage of patients who completed 25 weeks of double-blind treatment with specified changes from their baseline ADAScog scores. The study had three treatment groups: Placebo, 4mg, and 12mg. The chart shows the cumulative percentage of patients completing the study along with the change in ADAScog scores. The percentage of randomized patients who completed the study for each treatment group is also provided.*

rivastigmine-figure06 - rivastigmine fig6

rivastigmine-figure06 - rivastigmine fig6

rivastigmine-figure07 - rivastigmine fig7

rivastigmine-figure07 - rivastigmine fig7

rivastigmine-figure08 - rivastigmine fig8

rivastigmine-figure08 - rivastigmine fig8

rivastigmine-chemical-structure - rivastigmine str

rivastigmine-chemical-structure - rivastigmine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.